XML 62 R40.htm IDEA: XBRL DOCUMENT
v3.20.1

LICENSE AGREEMENTS (Details) | Jun. 14, 2019 USD ($) | Sep. 28, 2018 | Sep. 27, 2018 | Sep. 15, 2016 USD ($) | Dec. 15, 2014 item | Dec. 31, 2019 USD ($) | Dec. 31, 2018 USD ($)
--- | --- | --- | --- | --- | --- | --- | ---
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Amount due to Janssen Biotech, Inc. |  |  |  |  |  | $ 14,269,000 | $ 2,610,000
Janssen Biotech | Former Collaboration Agreement |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Number of agreed upon studies | item |  |  |  |  | 2 |  |
Percentage of costs to be paid by Geron |  |  |  |  | 50.00% |  |
Percentage of costs to be paid by Janssen |  |  |  |  | 50.00% |  |
Percentage of costs to be paid by Geron before termination of Collaboration Agreement |  |  | 50.00% |  |  |  |
Percentage of costs to be paid by Geron after termination of Collaboration Agreement |  | 100.00% |  |  |  |  |
Amount due to Janssen Biotech, Inc. |  |  |  |  |  | $ 14,269,000 |
Janssen Biotech | Clinical Supply Agreement |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Expected payment for drug product upon shipment | $ 7,500,000 |  |  |  |  |  |
Janssen Biotech | Clinical Supply Agreement | Maximum |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Expected payment for drug substance and raw materials upon testing and confirmation | $ 6,700,000 |  |  |  |  |  |
Janssen Pharmaceuticals Inc | License agreements |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Upfront payment received under license agreement |  |  |  | $ 5,000,000 |  |  |
Aggregate maximum total payments for development and regulatory milestones under license agreement |  |  |  | $ 75,000,000 |  |  |
Tiered royalties percentage range |  |  |  | low single digit |  |  |
Janssen Pharmaceuticals Inc | License Arrangement IP Exclusively Licensed |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Percentage of costs to be paid by Geron |  |  |  | 50.00% |  |  |
Percentage of costs to be paid by Janssen Pharmaceuticals |  |  |  | 50.00% |  |  |

X
- Definition Represents the percentage of costs that the company must pay after the termination of the Collaboration Agreement. + References No definition available. + Details
Name: | gern_CollaborativeArrangementAfterTerminationCostSharingPercentageOfEntity
Namespace Prefix: | gern_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the percentage of costs that the company must pay before the termination of the Collaboration Agreement + References No definition available. + Details
Name: | gern_CollaborativeArrangementBeforeTerminationCostSharingPercentageOfEntity
Namespace Prefix: | gern_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the percentage of costs that Janssen must pay during certain phases of the agreement. + References No definition available. + Details
Name: | gern_CollaborativeArrangementCostSharingPercentageOfCounterparty
Namespace Prefix: | gern_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the percentage of costs that Geron must pay during certain phases of the agreement. + References No definition available. + Details
Name: | gern_CollaborativeArrangementCostSharingPercentageOfEntity
Namespace Prefix: | gern_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the number of agreed upon studies. + References No definition available. + Details
Name: | gern_CollaborativeArrangementNumberOfStudies
Namespace Prefix: | gern_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Carrying amount as of the balance sheet date of obligations due to counterparty. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer). + References No definition available. + Details
Name: | gern_DueToCounterParty
Namespace Prefix: | gern_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Expected payment for drug product upon shipment. + References No definition available. + Details
Name: | gern_ExpectedPaymentForDrugProductUponShipment
Namespace Prefix: | gern_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Expected payment for drug substance and raw materials upon testing and confirmation. + References No definition available. + Details
Name: | gern_ExpectedPaymentForDrugSubstanceAndRawMaterialsUponTestingAndConfirmation
Namespace Prefix: | gern_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition License agreement cost sharing percentage of counterparty. + References No definition available. + Details
Name: | gern_LicenseAgreementCostSharingPercentageOfCounterparty
Namespace Prefix: | gern_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition License agreement cost sharing percentage of entity. + References No definition available. + Details
Name: | gern_LicenseAgreementCostSharingPercentageOfEntity
Namespace Prefix: | gern_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition License agreement maximum additional potential payment to be received upon achievement of certain development and regulatory milestones. + References No definition available. + Details
Name: | gern_LicenseAgreementMaximumAdditionalPotentialPaymentToBeReceivedUponAchievementOfCertainDevelopmentAndRegulatoryMilestones
Namespace Prefix: | gern_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Represents the range of tiered royalty percentages to be applied to worldwide net sales of licensed products under the License Agreement. + References No definition available. + Details
Name: | gern_LicenseAgreementTieredRoyaltiesPercentageRange
Namespace Prefix: | gern_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Upfront payment under License Agreement. + References No definition available. + Details
Name: | gern_UpfrontPaymentUnderLicenseAgreement
Namespace Prefix: | gern_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=gern_JanssenBiotechIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=gern_FormerCollaborativeArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=gern_ClinicalSupplyAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=gern_JanssenPharmaceuticalsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=gern_LicenseArrangementIPExclusivelyLicensedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |